The India Pharmaceutical Market was valued at USD 61.36 Billion in 2024 and is forecast to reach USD 174.31 Billion by 2033. The market is expected to grow at a CAGR of 11.32% during the forecast period 2025–2033. This growth is driven by robust generics production, a skilled workforce, increasing domestic healthcare demand, government support for local API production, and advances in biotechnology.

STUDY ASSUMPTION YEARS

• Base Year: 2024
• Historical Year/Period: 2019-2024
• Forecast Year/Period: 2025-2033

INDIA PHARMACEUTICAL MARKET KEY TAKEAWAYS

• Current Market Size: USD 61.36 Billion in 2024
• CAGR: 11.32%
• Forecast Period: 2025-2033
• The Indian pharmaceutical market thrives on powerful generic drug production and cost-efficient manufacturing with a competent workforce.
• The prevalence of chronic diseases, such as diabetes and cardiovascular conditions, drove chronic therapeutic drugs to represent 38.1% share in the 12 months ending January 2024.
• Government initiatives like the Production-Linked Incentive (PLI) scheme promote local API manufacturing, reducing import dependence.
• Investment of ₹1,000 crore by the Government of India in 2024 enhanced innovation in biotechnology and healthcare solutions.
• Digital transformation with AI/ML adoption has improved drug discovery and clinical development efficiency.

Sample Request Link: https://www.imarcgroup.com/india-pharmaceutical-market/requestsample

MARKET TRENDS

India's growing focus on self-reliance in Active Pharmaceutical Ingredients (API) production is notable, supported by government initiatives like the Production Linked Incentive (PLI) scheme. The allocation of Rs. 604 crore (USD 69.76 million) under the PLI scheme in the first half of FY25 (April-September 2024) fosters indigenous API manufacturing, enhances supply chain resilience, and promotes greater self-reliance in key pharmaceutical areas.

Biologics and biosimilars have emerged as significant growth drivers in the Indian pharmaceutical market. The biosimilars segment is expected to grow at a CAGR of 22%, reaching USD 12 billion by 2025, and accounting for nearly 20% of the country’s pharmaceutical market. These products address unmet medical needs and offer export potential by providing cost-effective substitutes to complex biologic medicines.

Digital transformation is reshaping pharmaceutical operations across manufacturing, supply chain, and patient care. Approximately 79% of pharma leaders highlight AI/ML adoption to boost drug discovery and clinical development efficiency, while 50% emphasize regulatory simplification. Telemedicine and e-pharmacies are making healthcare more accessible, enhancing the industry's efficiency and regulatory adherence.

MARKET GROWTH FACTORS

The India pharmaceutical market growth is propelled by rising demand for affordable medicines due to a high prevalence of chronic diseases like diabetes and cardiovascular conditions. Growing healthcare awareness and expanded access to medical services, especially in rural areas, further stimulate domestic market growth. The market’s competitive pricing and quality medicines enhance its global supplier strength.

Government support, especially the Production-Linked Incentive (PLI) scheme, encourages local API manufacturing, reducing import dependency and fostering self-reliance. Additionally, investments of ₹1,000 crore in 2024 for biotechnology innovation underpin advancements in biosimilars and specialized therapies, rapidly evolving India as a center for healthcare innovation and growth.

Increasing biotechnology investments and regulatory reforms strengthen India’s pharmaceutical ecosystem. Initiatives attracting private and foreign funding facilitate research and development in biosimilars, oncology, and chronic disease therapies. Expanding healthcare infrastructure coupled with digital advances positions India as a global pharmaceutical leader with an optimistic growth trajectory.

MARKET SEGMENTATION

Analysis by Type:

• Pharmaceutical Drugs
• Cardiovascular Drugs
• Dermatology Drugs
• Gastrointestinal Drugs
• Genito-Urinary Drugs
• Hematology Drugs
• Anti-Infective Drugs
• Metabolic Disorder Drugs
• Musculoskeletal Disorder Drugs
• Central Nervous System Drugs
• Oncology Drugs
• Ophthalmology Drugs
• Respiratory Diseases Drugs
• Biologics
• Monoclonal Antibodies (MAbS)
• Therapeutic Proteins
• Vaccines

Pharmaceutical drugs dominate due to wider accessibility, increased health awareness, and growing chronic and acute disorders. Strong government initiatives for healthcare infrastructure and research funding improve drug availability and affordability.

Analysis by Nature:

• Organic
• Conventional

Conventional drugs are leading due to widespread use in acute and chronic disease treatment. Small molecule drugs are popular for offering affordable, efficacious medications, supported by strong generics manufacturing. In 2024, 19 new drugs, including first-in-class chronic disease drugs, were approved, showcasing ongoing innovation.

REGIONAL INSIGHTS

North India is the largest region in the India pharmaceutical market, driven by dense population, advanced healthcare infrastructure, and increasing healthcare awareness. The 2024 record of 1.39 crore appointments at Delhi's Mohalla clinics exemplifies this growth. The region’s strategic location and logistics network enhance distribution efficiency domestically and internationally.

RECENT DEVELOPMENTS & NEWS

• January 2024: Glenmark Pharmaceuticals and Pfizer partnered to launch Abrocitinib in India, an oral treatment for moderate-to-severe atopic dermatitis, co-marketed as JABRYUS and CIBINQO.
• June 2024: Orchid Pharma launched Cefepime-Enmetazobactam for treating cUTI, HAP, and VAP, collaborating with Cipla for distribution across India.
• December 2024: Mankind Pharma acquired 100% stake in Bharat Serums and Vaccines for INR 13,630 crores to enhance leadership in women’s health and critical care.
• December 2024: Mankind Pharma and Innovent Biologics partnered to exclusively license and commercialize sintilimab, a PD-1 immunotherapy for cancer treatment.
• December 2024: Lupin Limited acquired Huminsulin from Eli Lilly in India, bolstering its diabetes portfolio.

KEY PLAYERS

• Abbott India Limited
• Aurobindo Pharma Limited
• Biocon Limited
• Cadila Pharmaceuticals
• Cipla Limited
• Divi's Laboratories Limited
• Dr. Reddy’s Laboratories Ltd
• GSK plc
• Lupin Limited
• Mankind Pharma Limited
• Novartis India (Novartis AG)
• Pfizer Inc
• Procter & Gamble Health Limited
• Sun Pharmaceutical Industries Ltd
• Torrent Pharmaceuticals Ltd

Customization Note:

If you require any specific information that is not covered currently within the scope of the report, we will provide the same as a part of the customization.

ABOUT US

IMARC Group is a global management consulting firm that helps the world’s most ambitious changemakers to create a lasting impact. The company provide a comprehensive suite of market entry and expansion services. IMARC offerings include thorough market assessment, feasibility studies, company incorporation assistance, factory setup support, regulatory approvals and licensing navigation, branding, marketing and sales strategies, competitive landscape and benchmarking analyses, pricing and cost research, and procurement research.

CONTACT US

IMARC Group,

134 N 4th St. Brooklyn, NY 11249, USA,

Email: [email protected],

Tel No: (D) +91-120-433-0800,

United States: +1-201-971-6302